Global Information
회사소개 | 문의 | 위시리스트

세계의 희귀의약품 시장 : 산업 분석과 전망

Global Orphan Drugs Market: Industry Analysis & Outlook 2018-2022

리서치사 Koncept Analytics
발행일 2018년 07월 상품 코드 351312
페이지 정보 영문 79 Pages
가격
US $ 1,000 ₩ 1,227,000 PDF by E-mail (Single User License)
US $ 1,100 ₩ 1,350,000 Hard Copy Mail Delivery
US $ 1,300 ₩ 1,596,000 PDF by E-mail (Corporate User License)


세계의 희귀의약품 시장 : 산업 분석과 전망 Global Orphan Drugs Market: Industry Analysis & Outlook 2018-2022
발행일 : 2018년 07월 페이지 정보 : 영문 79 Pages

세계 희귀의약품(희귀질환용 치료제) 시장의 최신 동향과 향후 전망에 대해 분석했으며, 희귀의약품의 전체적인 시장 구조 및 동향 전망, 지역별 상세 동향, 주요 시장 촉진·억제요인, 주요 기업의 개요·실적·전략 등에 대해 조사분석하여 전해드립니다.

제1장 개요

제2장 세계의 희귀의약품 시장

  • 희귀의약품 시장의 매출
  • 희귀의약품 시장의 매출 예측
  • 희귀의약품의 제품별 시장
  • 처방약 시장에서 희귀의약품의 점유율
  • 처방약 시장에서의 희귀의약품 점유율 예측

제3장 지역별 분석

  • 아메리카
    • 미국
    • 캐나다
  • 유럽
  • 아시아
    • 일본
    • 인도

제4장 시장 역학

  • 성장요인
  • 주요 동향
  • 과제

제5장 경쟁 환경

  • 세계 시장
  • 유럽 시장

제6장 기업 개요

KSA 17.07.03

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Orphan diseases are typically life-threatening or chronically debilitating for which no or inadequate alternative treatments are available. An orphan disease refers to any rare disease which affects a smaller share of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

Orphan drug market is likely to witness a growth in future with increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The US and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan drug designations. Asia is likely to experience further growth with increasing orphan designations in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends & development of this market include rise in orphan drug approvals, accelerating pipeline sales of orphan drugs, development of drug therapies and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report "Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and Asia along with the global market. The report profiles key players of the market including Roche holding AF, Novartis International AG, Bristol-Myers Squibb and Celgene Corporation.

Table of Contents

1. Overview

  • 1.1 Orphan Disease
  • 1.2 Orphan Drugs

2. Global Orphan Drugs Market

  • 2.1 Global Orphan Drugs Market by Value
  • 2.2 Global Orphan Drugs Market Forecast by Value
  • 2.3 Global Orphan Drugs Market by Product
    • 2.3.1 Global Revlimid Drug Revenue Forecast
    • 2.3.2 Global Rituxan Drug Revenue Forecast
    • 2.3.3 Global Opvido Drug Revenue Forecast
  • 2.4 Global Orphan Drugs Market by Therapy
    • 2.4.1 Global Oncology Therapy Market Forecast by Value
    • 2.4.2 Global Blood Therapy Market Forecast by Value
    • 2.4.3 Global Central Nervous System Therapy Market Forecast by Value

3. Regional Market Analysis

  • 3.1 The Americas
    • 3.1.1 The US Orphan Drugs Spending Forecast
    • 3.1.2 The US Orphan Drug by Designation Volume
    • 3.1.3 The US Orphan Drug Average & Median Cost per Patient
    • 3.1.4 The US Orphan Drug Average & Median Cost per Patient Forecast
    • 3.1.5 Canada Orphan Drugs Spending
    • 3.1.6 Canada Orphan Drugs Spending Forecast
  • 3.2 Europe
    • 3.2.1 Europe Orphan Drugs Market Forecast by Value
    • 3.2.2 Europe Orphan Drugs Market by Product
    • 3.2.3 Europe Orphan Drug by Designation Volume
  • 3.3 Asia
    • 3.3.1 Japan Orphan Drug by Designation Volume
    • 3.3.2 India Orphan Drugs Market Forecast by Value

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Prolonged Orphan Drug Market Exclusivity
    • 4.1.2 Increasing Sales of Prescription Drugs
    • 4.1.3 Attractive Orphan Drug Policies
    • 4.1.4 Rising Healthcare Expenditure
    • 4.1.5 Improving Economic Condition
    • 4.1.6 Increasing Prevalence of Chronic Diseases
  • 4.2 Key Trends & Development
    • 4.2.1 Rise in Orphan Drug Approvals
    • 4.2.2 Accelerating Pipeline Sales of Orphan Drugs
    • 4.2.3 Development of Drug Therapies
    • 4.2.4 Increasing Scope of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Costs
    • 4.3.2 Lack of Diagnostic Systems and Trained Professionals
    • 4.3.3 Insufficient Disease Information and Research Participants
    • 4.3.4 Rising Competition from Generic Industry

5. Competitive Landscape

  • 5.1 Global Market
    • 5.1.1 Revenue and Market Cap Comparison
    • 5.1.2 Global Orphan Drugs Market Share by Company
    • 5.1.3 Global Oncology Orphan Drugs Market Share by Company
  • 5.2 The US
    • 5.2.1 The US Top 10 Orphan Drugs Sales by Company
  • 5.3 Europe
    • 5.3.1 Europe Orphan Drugs Market Share by Company

6. Company Profiles

  • 6.1 Novartis International AG
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Roche Holding AG
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Bristol-Myers Squibb
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Celgene Corporation
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Types of Orphan Drugs
  • Orphan Drug Development
  • Global Orphan Drugs Market by Value (2013-2017)
  • Global Orphan Drugs Market Forecast by Value (2018-2022)
  • Global Orphan Drugs Market by Product (2017)
  • Global Revlimid Drug Revenue Forecast (2017-2022)
  • Global Rituxan Drug Revenue Forecast (2017-2022)
  • Global Opvido Drug Revenue Forecast (2017-2022)
  • Global Orphan Drugs Market by Therapy (2017)
  • Global Oncology Therapy Market Forecast by Value (2017-2022)
  • Global Blood Therapy Market Forecast by Value (2017-2022)
  • Global Central Nervous System Therapy Market Forecast by Value (2017-2022)
  • The US Orphan Drugs Spending Forecast (2017-2022)
  • The US Orphan Drug by Designation Volume (2013-2017)
  • The US Orphan Drug Average & Median Cost per Patient (2013-2017)
  • The US Orphan Drug Average & Median Cost per Patient Forecast (2018-2022)
  • Canada Orphan Drugs Spending (2013-2017)
  • Canada Orphan Drugs Spending Forecast (2018-2022)
  • Europe Orphan Drugs Market Forecast by Value (2017-2022)
  • Europe Orphan Drugs Market by Product (2017)
  • Europe Orphan Drug by Designation Volume (2013-2017)
  • Japan Orphan Drug by Designation Volume (2013-2017)
  • India Orphan Drugs Market Forecast by Value (2017-2022)
  • Global Prescription Drugs Sales (2013-2022)
  • Global Healthcare Expenditure (2013-2017)
  • Global GDP Per Capita (2013-2017)
  • Global Cancer Prevalence (2012-2030E)
  • The US FDA Orphan Drug Approvals (2010-2017)
  • The US Orphan Novel Drug Approvals (2010-2017)
  • Global Worldwide Orphan Drug Pipeline Sales (2018-2024)
  • Projection of Top 10 Orphan Drugs in Development (phase III/filed) by NPV* (2018)
  • Global Orphan Drugs Market Share by Company (2017/2024)
  • Global Oncology Orphan Drugs Market Share by Company (2017/2024)
  • Europe Orphan Drugs Market Share by Company (2017)
  • Novartis Sales by Segment (2017)
  • Novartis Net Sales and Net Income (2013-2017)
  • Roche Sales by Segments (2017)
  • Roche Sales and Net Income (2013-2017)
  • Bristol-Myers Squibb Revenue by Region (2017)
  • Bristol-Myers Squibb Total Revenue and Net Earnings (2013-2017)
  • Bristol-Myers Squibb R&D Expenditure (2015-2017)
  • Celgene Revenue by Region (2017)
  • Celgene Total Revenue and Net Income (2013-2017)

List of Tables

  • Orphan Disease Prevalence in Different Nations
  • Orphan Drug Market Exclusivity
  • Orphan Drug Policies
  • Prices and Prevalence of Some Orphan Drugs in the US (2017)
  • Key Players - Revenue & Market Cap Comparison (2017)
  • The US Top 10 Orphan Drugs Sales by Company (2017)
  • Novartis Agreements (2018)
  • Novartis Major Product Approvals (2018)
  • Roche Agreements (2017/2018)
  • Roche Product Approvals (2018)
  • Bristol-Myers Squibb Agreements (2018)
  • Celgene R&D Expenditure (2015-2017)
Back to Top
전화 문의
F A Q